EVO vs IQV vs FTRE Stock Comparison

Evotec SE, Iqvia Holdings and Fortrea Holdings Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (TEM) Create a free account to keep reading and compare up to 10 companies.
EVO Evotec SE
$1.57 +1.3% 1M -61.9% 1Y
Market cap
$571.80M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Research Healthcare
IQV Iqvia Holdings Inc.
$271.68 +0.7% 1M +25.0% 1Y
Market cap
$45.59B
P/E
32.7x
Revenue (TTM)
$17.31B
Div. yield
–
Contract Research Healthcare
8 wins
FTRE Fortrea Holdings Inc.
$24.43 +22.8% 1M +135.1% 1Y
Market cap
$2.41B
P/E
–
Revenue (TTM)
$2.68B
Div. yield
–
Contract Research Healthcare
1 win

Head to Head

9 decided of 12

Iqvia Holdings leads on 8 of the 12 questions below (Iqvia Holdings 8, Fortrea Holdings 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionEVOIQVFTRELeader
Larger companyMarket capitalisation $571.80M $45.59B $2.41B IQV
Cheaper on earningsLower P/E, profitable companies only — 32.7x -28.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 22.4x 30.2x IQV
Faster revenue growthRevenue growth, trailing twelve months — +8.8% -2.1% IQV
More profitableNet margin, trailing twelve months — 8.1% -3.2% IQV
Better return on capitalReturn on invested capital — 8.2% -0.7% IQV
Less leveragedLower net debt / EBITDA — 3.9x 13.1x IQV
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -61.9% +25.0% +135.1% FTRE
Better 5-year returnAnnualised price return, 5 years — +1.1%/yr — –
Less volatileAnnualised volatility, 1 year 58.0% 40.3% 70.3% IQV
Higher overall scoreMean of the five percentile scores vs peers — 71/100 50/100 IQV

Percentile Scorecard

EVOIQVFTRE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisEVOIQVFTRE
Valuation – 80 #3 of 11 90 #2 of 11
Growth – 80 #3 of 11 60 #5 of 11
Profitability – 90 #2 of 11 50 #6 of 11
Financial Health 92 #2 of 13 33 #9 of 13 0 #13 of 13
Shareholder Returns – – –
Overall – 71 50
  • EVO ranked among 13 companies in Pharma Services
  • IQV ranked among 13 companies in Pharma Services
  • FTRE ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodEVOIQVFTRESPY
1 month +1.3%+0.7%+22.8% -0.2%
3 months -19.9%+11.7%+18.0% +3.9%
6 months -47.3%+70.9%+127.0% +8.2%
Year to date -49.0%+20.5%+41.6% +12.9%
1 year -61.9%+25.0%+135.1% +12.3%
3 years -81.2%+51.0%-11.3% +87.4%
3 years, per year -42.8%+14.7%-3.9% +23.3%
5 years —+5.6%— +67.9%
5 years, per year —+1.1%— +10.9%
10 years —+276.8%— +261.1%
10 years, per year —+14.2%— +13.7%

Risk

MeasureEVOIQVFTRESPY
Volatility, 1Y 58.0%40.3%70.3% 12.7%
Downside volatility, 1Y 65.3%39.2%63.6% 12.7%
Beta vs S&P 500, 1Y 1.500.742.01 1.00
Return / volatility, 1Y -1.070.621.92 0.97
Max drawdown, 5Y -94.6%-51.5%-89.9% -25.4%
From 52-week high -62.2%-2.8%0.0% -1.2%
52-week high $4.15$279.38$24.43 $779.14
52-week low $1.35$156.66$8.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleEVOIQVFTRE
P/E now vs peer median —median 32.1x 32.1xmedian 32.1x -27.2xmedian 32.1x
P/S now vs peer median —median 2.6x 2.6xmedian 2.6x 0.9xmedian 2.6x
EV/EBITDA now vs peer median —median 38.1x 16.9xmedian 38.1x 47.5xmedian 38.1x
P/FCF now vs peer median —median 21.5x 21.5xmedian 21.5x 11.9xmedian 21.5x
P/B now vs peer median 0.7xmedian 3.1x 6.6xmedian 3.1x 4.4xmedian 3.1x
PEG now vs peer median —median 2.03 2.78median 2.03 0.57median 2.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsEVOIQVFTRE
Revenue – $17.31B $2.68B
Gross profit – $5.72B $516.60M
Operating income – $2.22B -$10.80M
Net income – $1.40B -$85.20M
Free cash flow – $2.08B $196.00M
EPS (diluted) – $8.35 $-0.90
Cash & equivalents $397.89M $2.25B $168.60M
Total debt $1.96B $16.07B $1.05B
Shares (diluted) – 167.00M 94.80M
Enterprise value -$1.04B $36.85B $1.79B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricEVOIQVFTRE
P/E – 32.1x -27.2x
P/FCF – 21.5x 11.9x
P/Operating cash flow – 16.4x 10.2x
P/S – 2.6x 0.9x
P/B 0.7x 6.6x 4.4x
P/Tangible book 0.7x 21.8x -37.1x
EV/EBITDA – 16.9x 47.5x
EV/EBIT – 26.3x -297.1x
EV/Revenue – 3.4x 1.2x
EV/FCF – 28.1x 16.4x
EV/Operating cash flow – 21.4x 14.1x
PEG (3Y EPS CAGR) – 2.78 0.57

Growth

14 metrics
MetricEVOIQVFTRE
Revenue growth (1Y) – 8.8% -2.1%
Revenue CAGR (3Y) – 5.2% -0.1%
Gross profit growth (1Y) – 6.6% -4.2%
Gross profit CAGR (3Y) – 3.4% -10.2%
Operating income growth (1Y) – 1.7% 98.8%
Operating income CAGR (3Y) – 6.2% -27.7%
Net income growth (1Y) – 9.0% 91.7%
Net income CAGR (3Y) – 7.8% -38.4%
EPS growth (1Y) – 11.7% 92.1%
EPS CAGR (3Y) – 11.5% -47.7%
Operating cash flow growth (1Y) – -2.4% 359.7%
Operating cash flow CAGR (3Y) – 11.7% -3.4%
Free cash flow growth (1Y) – -6.0% 290.1%
Free cash flow CAGR (3Y) – 16.3% 0.8%

Profitability

14 metrics
MetricEVOIQVFTRE
Gross margin – 33.1% 19.3%
EBITDA margin – 20.0% 2.5%
Operating margin – 12.8% -0.4%
Pretax margin – 9.0% -2.9%
Net margin – 8.1% -3.2%
FCF margin – 12.0% 7.3%
Operating cash flow margin – 15.8% 8.5%
Return on equity – 21.4% -16.2%
Return on assets – 4.6% -3.2%
Return on invested capital – 8.2% -0.7%
Return on capital employed – 9.9% -0.6%
Asset turnover – 0.6x 1.0x
Cash conversion (OCF / net income) – 2.0x -2.7x
Stock comp / revenue – 1.8% 2.3%

Financial Health

11 metrics
MetricEVOIQVFTRE
Debt / assets 30.2% 52.7% 38.8%
Debt / equity 0.7x 2.4x 2.0x
Net debt / EBITDA – 3.9x 13.1x
Debt / FCF – 7.7x 5.4x
Liabilities / assets 57.7% 77.7% 80.7%
Equity / assets 42.3% 22.3% 19.3%
Interest coverage – 2.8x –
Current ratio 2.3x 0.8x 1.0x
Quick ratio 1.6x 1.0x 0.9x
Cash ratio 1.2x 0.3x 0.2x
Altman Z-score – 2.27 0.86

Shareholder Returns

7 metrics
MetricEVOIQVFTRE
Dividend yield – – –
Net buyback yield – 2.6% –
Shareholder yield 0.0% 2.6% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusEVOIQVFTRE
Forward P/E – 22.4xFY2026 30.2xFY2026
EPS, next fiscal year $-0.72FY2026 $12.14FY2026 $0.81FY2026
EPS growth, next FY – +1.8%FY2026 +88.4%FY2026
EPS growth, the year after – +13.3% +22.2%
Revenue, next fiscal year $682.51MFY2026 $18.58BFY2026 $2.77BFY2026
Revenue growth, next FY -26.0%FY2026 +13.9%FY2026 +1.7%FY2026
Revenue growth, the year after +23.4% -3.5% -3.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersEVOIQVFTRE
Held by institutions 0.9% 94.1% 100.0%
Institutions holding 35 1,083 329
Change in shares held, QoQ -60.2% +0.3% -0.2%
Institutions buying 18 530 139
Institutions selling 7 424 108
Buyers to sellers 2.57 1.25 1.29

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

EVOIQVFTRE
EVO 1.00 0.26 0.20
IQV 0.26 1.00 0.57
FTRE 0.20 0.57 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, EVO, IQV and FTRE?

Iqvia Holdings (IQV) is the largest by market capitalisation: Evotec SE (EVO) $571.80M, Iqvia Holdings (IQV) $45.59B, Fortrea Holdings (FTRE) $2.41B.

Which company is growing faster?

Iqvia Holdings (IQV) grew revenue fastest over the trailing twelve months: Iqvia Holdings (IQV) +8.8%, Fortrea Holdings (FTRE) -2.1%.

Which company is more profitable?

Iqvia Holdings (IQV) has the highest net margin (Iqvia Holdings (IQV) 8.1%, Fortrea Holdings (FTRE) -3.2%). On return on invested capital, Iqvia Holdings (IQV) leads (Iqvia Holdings (IQV) 8.2%, Fortrea Holdings (FTRE) -0.7%).

Which stock has performed better?

Over the past year Fortrea Holdings (FTRE) returned the most: Evotec SE (EVO) -61.9%, Iqvia Holdings (IQV) +25.0%, Fortrea Holdings (FTRE) +135.1%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Iqvia Holdings (IQV) has been the steadiest (Evotec SE (EVO) 58.0%, Iqvia Holdings (IQV) 40.3%, Fortrea Holdings (FTRE) 70.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, EVO, IQV and FTRE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Iqvia Holdings (IQV) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.